加减香砂六君子汤联合三联疗法治疗慢性萎缩性胃炎临床观察

来源期刊：广州医药 | 28-32 发布时间：2021-12-21 收稿时间：2025/11/13 17:37:22 阅读量：22

作者：: 罗曼虹,

关键词：: 慢性萎缩性胃炎加减香砂六君子汤三联疗法; Chronic atrophic gastritis Jiajianxiangshaliujunzi decoction Triple therapy

DOI：: 10.3969/j.issn.1000-8535.2019.01.007

收稿时间：: 2018-07-25
修订日期：
接收日期：
引用总数：: 0

目的研究加减香砂六君子汤联合三联疗法治疗慢性萎缩性胃炎的临床疗效。方法将100例慢性萎缩性胃炎患者随机分为对照组和观察组各50例,对照组患者给予三联疗法而观察组在对照组基础上辨证使用加减香砂六君子汤加减进行治疗。对临床疗效进行评估,观察两组患者临床症状并测定血清中超氧化物歧化酶（SOD）、丙二醛（MDA）水平的变化,统计两组的幽门螺杆菌（Hp）转阴率及复发率、根除率。结果治疗以后统计有效率,观察组为92%,而对照组仅有76%,胃胀、胃痛、痞满、反酸、饮食减少等症状均缓解,各症状的积分治疗后均降低,两组相比其差异有统计学意义,观察组的Hp转阴率为92.0%,对照组Hp转阴率为68.0% ,两组Hp转阴率比较,差异有统计学意义。两组SOD水平均较治疗前上升,MDA水平均较治疗前下降,SOD水平高于对照组,MDA水平低于对照组,差异均有统计学意义（P<0.05）。结论加减香砂六君子汤联合三联疗法治疗慢性萎缩性胃炎可显著改善患者的临床症状,有良好的应用前景。

Objective To observe the clinical effect of Jiajianxiangshaliujunzi decoction combined with triple therapy for chronic atrophic gastritis. Methods We selected 100 cases of patients with chronic atrophic gastritis of intertwined,and divided them into the control group and the observation group randomly with 50 cases in each group. The control group was given triple therapy for treatment,while the observation group was additionally given Jiajianxiangshaliujunzi decoction based on the syndrome differentiation for treatment. We observed the changes of clinical symptoms and levels of superoxide dismutase（SOD） and malondialdehyde（MDA） in serum of both groups. The negative conversion rate,recurrence rate and eradication rate of Helicobacter pylori （Hp） in 2 groups were statistically analyzed,in both groups and the clinical effect. Results After treatment,the total effective rates were counted: the observation group was 92%,and the control group was only 76%. The symptoms such as stomach distention,stomachache,distention and fullness,acid reflux,and diet reduction were reduced after the treatment. The difference between the two groups had statistical significance. In the two groups of stomachache,fullness and boredom,low appetite and acid regurgitation scores were all lower than those before treatment,and the differences were statistically significant. The negative rate of Hp in the observation group was 92%,while the negative rate of Hp in the control group was 68%. There was difference between the two groups in the negative rate of Hp. The levels of SOD in both groups were higher than those before treatment,and the levels of MDA were lower than those before treatment,differences being significant（P< 0.05）;the level of SOD in the observation group was higher than that in the control group,and the level of MDA was lower than that in the control group. Difference was statistically significant. （P< 0.05）. Conclusion Jiajianxiangshaliujunzi decoction combined with triple therapy for chronic atrophic gastritis may improve clinical symptoms of patients,and promote the negative rate of Hp as well as the clinical effect.

1、何虹,刘洁珍,李凌汉,等. 中药熏洗与膝关节自我锻炼管理对老年骨性膝关节炎功能康复的影响[J]. 广州医药,2018,49(4):55-57.

2、刘晓如,肖爱美,戴乾汉,等. 奥美拉唑镁肠溶片联合抗菌药物治疗消化性溃疡的临床疗效[J]. 现代医院,2017,17(10):1519-1521.

3、刘庭玉,庄雅,党旖旎,等. 根除幽门螺杆菌联合叶酸口服3个月治疗慢性萎缩性胃炎的长期随访研究[J]. 中华消化杂志,2016,36(11):734-739.

4、柳华,杨梅,代二庆. 善胃系列方分型论治慢性萎缩性胃炎癌前病变的疗效研究[J]. 中国全科医学,2016,19(19):2348-2351.

5、张淼,杨沈秋,孙兴华,等. 参芪健胃颗粒治疗慢性萎缩性胃炎的临床研究[J]. 中国临床药理学杂志,2016,32(16):1460-1463.

6、屈健,奉继运,张文达. 三联疗法治疗幽门螺旋杆菌感染消化性溃疡的临床分析[J]. 广州医药,2010,41(6):27-28.

7、贾宝洋,关晓辉,杨志平,等. 新序贯疗法与三联疗法治疗幽门螺杆菌阳性萎缩性胃炎的临床疗效对比[J]. 中国老年学,2016,36(6):1386-1387.

8、张声生,唐旭东,黄穗平,等. 慢性胃炎中医诊疗专家共识意见(2017)[J]. 中华中医药杂志,2017(7):3060-3064.

9、王海燕,王柏青,李甜甜,等. 雷贝拉唑三联疗法在萎缩性胃炎并发幽门螺杆菌感染患者中的应用效果[J]. 中华医院感染学杂志,2017,27(9):2001-2004.

10、朱剑峰. 化肝煎加减联合叶酸对HP阳性慢性萎缩性胃炎患者胃蛋白酶原、白介素族及MDA水平影响研究[J]. 中华中医药学刊,2017,(6):1580-1582.

11、伦伟健,梁晓燕,黄鹤. 胃蛋白酶原、胃泌素17和HP感染与慢性萎缩性胃炎和肠上皮化生的相关性[J]. 广州医药,2018,49(3):26-28.

12、魏玮,杨洋. 慢性萎缩性胃炎诊治现状及中医药治疗优势[J]. 中医杂志,2016,57(1):36-40.